The 1.3 ATA Soft-Shell Problem: FDA Status, UHMS Warnings, and the Marketing Gap

What soft-shell "mild HBOT" is

Soft-shell portable hyperbaric chambers are fabric-walled units that pressurise to approximately 1.3 atmospheres absolute (ATA) using ambient air with a supplemental oxygen concentrator delivering 85-95% O₂ to the patient via mask or hood. The chambers are relatively lightweight, mobile, and significantly cheaper than clinical hard-shell units.

Commercial brands include OxyHealth, Summit to Sea, Macy-Pan, OxyNova, and others. The market has grown rapidly in the wellness, home-use, and alternative-medicine segments.

The FDA status

The FDA has cleared 1.3 ATA soft-shell chambers for one indication: acute mountain sickness (AMS). This is a long-standing clearance based on the clinical evidence that temporary pressurisation at 1.3 ATA can relieve altitude-related symptoms during descent or evacuation.

Every other use — traumatic brain injury, long COVID, autism, chronic fatigue, fibromyalgia, "general wellness," anti-aging, sports recovery — is off-label regardless of what marketing materials claim. Off-label does not mean illegal; US law allows practitioners to use FDA-cleared devices for non-cleared indications in their professional judgment. But the regulatory distinction matters:

• No insurance covers off-label 1.3 ATA HBOT
• Marketing claims that imply FDA endorsement for off-label indications are misleading
• Off-label uses have not been reviewed by FDA for safety and efficacy at this pressure

The UHMS consumer warning

The Undersea and Hyperbaric Medical Society — the clinical authority for hyperbaric medicine — has issued a formal consumer warning on uncertified soft-sided "bag" chambers. The specific concerns:

• Many soft-shell units sold are not registered with the FDA at all
• Many do not comply with NFPA 99 Chapter 14, the national fire-safety standard for health care facilities operating HBOT
• Many are not designed, fabricated, and certified to ASME PVHO-1 — the pressure-vessel standard that governs chamber construction
• Off-label use outside clinical facilities bypasses the training, maintenance, and emergency-response infrastructure that makes hospital-based HBOT safe

Both 2025 fatal HBOT chamber fires — the Oxford Center case in Michigan (January) and the Arizona case (July) — involved soft-shell or off-label operation.

The physiology is weaker than at clinical pressures

Beyond the regulatory and safety questions, the fundamental physiology at 1.3 ATA is weaker than at the clinical standard of 2.0 ATA with 100% O₂:

• At 1 ATA breathing room air: arterial PaO₂ ≈ 100 mmHg
• At 1.3 ATA breathing ~95% O₂: arterial PaO₂ ≈ 400 mmHg
• At 2.0 ATA breathing 100% O₂: arterial PaO₂ ≈ 1,500 mmHg

The therapeutic effect of HBOT scales with arterial oxygen tension — dissolved plasma oxygen bypasses hemoglobin-dependent delivery and reaches hypoperfused tissue. At 1.3 ATA, the pharmacokinetic driver is substantially weaker than at the clinical standard.

Whether this is enough to produce clinically meaningful effects for most indications remains the central question. Some positive signals exist at 1.3 ATA — most notably the Rossignol 2009 autism trial and the Harch 2017 veterans trial — but both have methodological debates, and larger follow-up trials have produced inconsistent results.

What the strongest HBOT research actually uses

The pattern across the strongest HBOT evidence is consistent: it uses 2.0 ATA or higher, not 1.3 ATA.

• Efrati Lab TBI, stroke, long COVID, fibromyalgia research — 2.0 ATA
• Zilberman-Itskovich 2022 long COVID RCT — 2.0 ATA
• Löndahl 2010 diabetic foot ulcer RCT — 2.5 ATA
• Weaver 2002 CO poisoning NEJM — 3.0 ATA
• Harch 2017 veterans trial — 1.5 ATA (modestly stronger than 1.3)
• Hachmo 2020 telomere study — 2.0 ATA

The pressure difference between 1.3 ATA and 2.0 ATA matters for both pharmacology and clinical outcome. Soft-shell 1.3 ATA chambers are a fundamentally different intervention from clinical hard-shell 2.0 ATA HBOT, and the evidence bases should not be conflated.

Legitimate uses of 1.3 ATA

Soft-shell mild HBOT is not useless. Legitimate use cases:

• Altitude sickness — the FDA-cleared indication with sound physiological rationale and demonstrated clinical utility
• General wellness with modest expectations — low-risk use for subjective wellbeing. Reasonable if the user understands the evidence base.
• Access-constrained users — some patients use 1.3 ATA home chambers because 2.0 ATA clinical HBOT is logistically or financially inaccessible. The weaker-but-not-zero therapeutic signal may be preferable to no treatment at all.
• Supervised home-use for selected off-label indications — with realistic expectations and appropriate safety protocols

Where 1.3 ATA falls short

• Not sufficient for UHMS-approved emergency indications (decompression sickness, CO poisoning, gas gangrene)
• Weaker evidence base than 2.0+ ATA for neurological indications
• Marketing claims frequently exceed the published clinical data
• Safety infrastructure (fire detection, trained operator presence, electronics exclusion) often weaker in off-label home use than in clinical facilities

The practical takeaway

Mild HBOT at 1.3 ATA is not inherently fraudulent, but the marketing around it frequently overstates the evidence. For UHMS-approved emergency and clinical indications, hard-shell chambers at 2.0 ATA or higher remain the clinical standard. For wellness-level use with realistic expectations, 1.3 ATA is a reasonable low-risk option. For serious off-label indications where the research evidence specifically uses 2.0 ATA (TBI, long COVID, chronic pain, anti-aging), the research-aligned choice is clinical-grade HBOT.

For a side-by-side look at hard-shell vs. soft-shell and all major chamber configurations, see our chambers reference and our comparison tool.